FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2928347831> ?p ?o ?g. }

• W2928347831 endingPage "188" @default.
• W2928347831 startingPage "183" @default.
• W2928347831 abstract "Acute kidney injury (AKI) is an important complication in burn patients. Recently, it has been recommended that hydroxyethyl starch (HES) be avoided in burn patients because it increases the incidence of AKI. Our purpose was to study incidence of AKI in critically ill burn patients resuscitated with Ringer's solution and supplements of HES. We conducted an observational study of 165 patients admitted to the critical care burn unit (with 30 ± 15% TBSA burned). The main outcome measures were incidence of AKI, contributions of colloids and crystalloids, various severity scores, comorbidities, complications and mortality. According to the RIFLE criteria, 10 (6.1%) patients presented with Risk, 11 (6.7%) presented with Injury and 11 (6.7%) presented with Failure. According to the AKIN criteria, 9.7% presented stage I, 3% stage II and 10.3% stage III. Replacement therapy (RRT) was performed in 15 patients (9.1%), but in 6 of them RRT was employed in the final stages of multi-organ failure. The incidence of AKI in severe burn patients is high according to the RIFLE or AKIN criteria and these patients experience more complications and higher mortality. Our study suggests that the use of HES in low doses in the burn resuscitation phase does not cause more AKI than resuscitation without HES, but further evaluation is required. Further studies should be conducted.La souffrance rénale aiguë (SRA) est une complication sévère des patients brûlés. Il a récemment été recommandé d’éviter les HydroxyEthylAmidons (HEA) chez les patients brûlés en raison de l’augmentation de l’incidence des SRA. Le but de ce travail est d’évaluer l’incidence de la SRA chez des patients réanimés avec du Ringer Lactate et des HEA. Il s’agit d’une étude observationnelle conduite auprès de 165 patients admis en réanimation pour brûlés (surface 30 +/-15%). Les principaux paramètre recueillis étaient la SRA, les cristalloïdes et colloïdes utilisés, les scores de gravité, les comorbidités, les complications et la mortalité. Selon la classification de Rifle, 10 (6,1%) patients étaient dans le groupe à risque, 11 (6,7%) avaient une souffrance rénale et 11 (6,7%) une insuffisance rénale. Selon les critères AKIN, 9,7% des patients étaient au stade 1, 3% au stade 2 et 10,3% au stade 3. Une épuration extra-rénale a été nécessaire à 15 (9,1%) patients, 6 d’entre eux étant à un stade avancé de défaillance multiviscérale. Basée sur les scores Rifle comme AKIN, l’incidence de souffrance rénale est élevée chez les brûlés et ceux qui en souffrent ont une morbidité et une mortalité plus élevées. Toutefois, notre étude laisse à penser que les patients ayant reçu des HEA n’ont pas plus de souffrance rénale que ceux n’en ayant pas reçu, des études plus poussées restant nécessaires." @default.
• W2928347831 created "2019-04-11" @default.
• W2928347831 creator A5004013682 @default.
• W2928347831 creator A5010430663 @default.
• W2928347831 creator A5026668992 @default.
• W2928347831 creator A5027149003 @default.
• W2928347831 creator A5029706486 @default.
• W2928347831 creator A5032441501 @default.
• W2928347831 creator A5042022075 @default.
• W2928347831 creator A5048959339 @default.
• W2928347831 creator A5078290856 @default.
• W2928347831 creator A5079379227 @default.
• W2928347831 creator A5088323374 @default.
• W2928347831 date "2016-09-30" @default.
• W2928347831 modified "2023-10-18" @default.
• W2928347831 title "Acute kidney injury in critically burned patients resuscitated with a protocol that includes low doses of Hydroxyethyl Starch." @default.
• W2928347831 cites W1479721491 @default.
• W2928347831 cites W1591078747 @default.
• W2928347831 cites W1967300023 @default.
• W2928347831 cites W1969692787 @default.
• W2928347831 cites W2003269194 @default.
• W2928347831 cites W2009946173 @default.
• W2928347831 cites W2020051827 @default.
• W2928347831 cites W2023765984 @default.
• W2928347831 cites W2024255913 @default.
• W2928347831 cites W2078470014 @default.
• W2928347831 cites W2083648339 @default.
• W2928347831 cites W2086066722 @default.
• W2928347831 cites W2089922917 @default.
• W2928347831 cites W2098340090 @default.
• W2928347831 cites W2104038351 @default.
• W2928347831 cites W2116065793 @default.
• W2928347831 cites W2125566349 @default.
• W2928347831 cites W2125738780 @default.
• W2928347831 cites W2132135347 @default.
• W2928347831 cites W2139937737 @default.
• W2928347831 cites W2144476991 @default.
• W2928347831 cites W2148706741 @default.
• W2928347831 cites W2152916122 @default.
• W2928347831 cites W2170344041 @default.
• W2928347831 cites W2171293195 @default.
• W2928347831 cites W2581605534 @default.
• W2928347831 cites W2613483874 @default.
• W2928347831 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5266234" @default.
• W2928347831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28149246" @default.
• W2928347831 hasPublicationYear "2016" @default.
• W2928347831 type Work @default.
• W2928347831 sameAs 2928347831 @default.
• W2928347831 citedByCount "6" @default.
• W2928347831 countsByYear W29283478312017 @default.
• W2928347831 countsByYear W29283478312019 @default.
• W2928347831 countsByYear W29283478312020 @default.
• W2928347831 countsByYear W29283478312022 @default.
• W2928347831 crossrefType "journal-article" @default.
• W2928347831 hasAuthorship W2928347831A5004013682 @default.
• W2928347831 hasAuthorship W2928347831A5010430663 @default.
• W2928347831 hasAuthorship W2928347831A5026668992 @default.
• W2928347831 hasAuthorship W2928347831A5027149003 @default.
• W2928347831 hasAuthorship W2928347831A5029706486 @default.
• W2928347831 hasAuthorship W2928347831A5032441501 @default.
• W2928347831 hasAuthorship W2928347831A5042022075 @default.
• W2928347831 hasAuthorship W2928347831A5048959339 @default.
• W2928347831 hasAuthorship W2928347831A5078290856 @default.
• W2928347831 hasAuthorship W2928347831A5079379227 @default.
• W2928347831 hasAuthorship W2928347831A5088323374 @default.
• W2928347831 hasConcept C120665830 @default.
• W2928347831 hasConcept C121332964 @default.
• W2928347831 hasConcept C126322002 @default.
• W2928347831 hasConcept C141071460 @default.
• W2928347831 hasConcept C146357865 @default.
• W2928347831 hasConcept C151730666 @default.
• W2928347831 hasConcept C166957645 @default.
• W2928347831 hasConcept C177713679 @default.
• W2928347831 hasConcept C2776376669 @default.
• W2928347831 hasConcept C2777051993 @default.
• W2928347831 hasConcept C2778165595 @default.
• W2928347831 hasConcept C2779412105 @default.
• W2928347831 hasConcept C2779541074 @default.
• W2928347831 hasConcept C2780472472 @default.
• W2928347831 hasConcept C2993242423 @default.
• W2928347831 hasConcept C42219234 @default.
• W2928347831 hasConcept C61511704 @default.
• W2928347831 hasConcept C71924100 @default.
• W2928347831 hasConcept C81182388 @default.
• W2928347831 hasConcept C86803240 @default.
• W2928347831 hasConcept C95457728 @default.
• W2928347831 hasConceptScore W2928347831C120665830 @default.
• W2928347831 hasConceptScore W2928347831C121332964 @default.
• W2928347831 hasConceptScore W2928347831C126322002 @default.
• W2928347831 hasConceptScore W2928347831C141071460 @default.
• W2928347831 hasConceptScore W2928347831C146357865 @default.
• W2928347831 hasConceptScore W2928347831C151730666 @default.
• W2928347831 hasConceptScore W2928347831C166957645 @default.
• W2928347831 hasConceptScore W2928347831C177713679 @default.
• W2928347831 hasConceptScore W2928347831C2776376669 @default.
• W2928347831 hasConceptScore W2928347831C2777051993 @default.
• W2928347831 hasConceptScore W2928347831C2778165595 @default.
• W2928347831 hasConceptScore W2928347831C2779412105 @default.

• next